Literature DB >> 14500678

Immunomodulatory role of CXCR2 during experimental septic peritonitis.

Traci L Ness1, Cory M Hogaboam, Robert M Strieter, Steven L Kunkel.   

Abstract

The loss of CXCR2 expression by neutrophils is a well-described, but poorly understood, consequence of clinical sepsis. To address the potential impact of this CXCR2 deficit during the septic response, we examined the role of CXCR2 in a murine model of septic peritonitis provoked by cecal ligation and puncture (CLP). CLP-induced mouse mortality was significantly attenuated with i.v. or i.p. administration of an affinity-purified murine CXCR2-specific polyclonal Ab. Mouse survival required Ab administration before and every 2 days following CLP. Furthermore, mice deficient in CXCR2 (CXCR2(-/-)) were significantly protected against CLP-induced mortality compared with control (CXCR2(+/+)) mice. The anti-CXCR2 Ab treatment delayed, but did not completely inhibit, the recruitment of leukocytes, specifically neutrophils, into the peritoneal cavity. Peritoneal macrophages from anti-CXCR2 Ab-treated mice exhibited markedly increased RNA and protein levels of several key proinflammatory cytokines and chemokines. Specifically, isolated preparations of these cells released approximately 11-fold more CXCL10 protein compared with peritoneal macrophages from control-treated or naive mice. CXCR2(-/-) mice had higher resting and CLP-induced levels of peritoneal CXCL10 compared with CXCR2(+/+) mice. Administration of a neutralizing, affinity-purified, murine CXCL10-specific polyclonal Ab before CLP in wild-type mice and every 2 days after surgery significantly increased mortality compared with control Ab-treated mice. Anti-CXCL10 treatment in CXCR2(-/-) mice negated the protective effect associated with the absence of CXCR2. In summary, these data demonstrate that the absence of CXCR2 protects mice from septic injury potentially by delaying inflammatory cell recruitment and enhancing CXCL10 expression in the peritoneum.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14500678     DOI: 10.4049/jimmunol.171.7.3775

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  Substance P in polymicrobial sepsis: molecular fingerprint of lung injury in preprotachykinin-A-/- mice.

Authors:  Akhil Hegde; Ramasamy Tamizhselvi; Jayapal Manikandan; Alirio J Melendez; Shabbir M Moochhala; Madhav Bhatia
Journal:  Mol Med       Date:  2010-02-08       Impact factor: 6.354

2.  Critical role for CXC ligand 10/CXC receptor 3 signaling in the murine neonatal response to sepsis.

Authors:  Alex G Cuenca; James L Wynn; Kindra M Kelly-Scumpia; Philip O Scumpia; Lizette Vila; Matthew J Delano; Clayton E Mathews; Shannon M Wallet; Westley H Reeves; Kevin E Behrns; Dina C Nacionales; Philip A Efron; Steven L Kunkel; Lyle L Moldawer
Journal:  Infect Immun       Date:  2011-04-25       Impact factor: 3.441

3.  Differential expression of CD14-dependent and independent pathways for chemokine induction regulates neutrophil trafficking in infection.

Authors:  Shalaka Metkar; Kwang Sik Kim; Jack Silver; Sanna M Goyert
Journal:  J Leukoc Biol       Date:  2012-05-16       Impact factor: 4.962

4.  Fas (CD95) induces macrophage proinflammatory chemokine production via a MyD88-dependent, caspase-independent pathway.

Authors:  William A Altemeier; Xiaodong Zhu; William R Berrington; John M Harlan; W Conrad Liles
Journal:  J Leukoc Biol       Date:  2007-06-18       Impact factor: 4.962

5.  Early enhanced local neutrophil recruitment in peritonitis-induced sepsis improves bacterial clearance and survival.

Authors:  Florin L Craciun; Elizabeth R Schuller; Daniel G Remick
Journal:  J Immunol       Date:  2010-11-01       Impact factor: 5.422

6.  Blockade of CD137 signaling counteracts polymicrobial sepsis induced by cecal ligation and puncture.

Authors:  Quang-Tam Nguyen; Seong-A Ju; Sang-Min Park; Sang-Chul Lee; Hideo Yagita; In Hee Lee; Byung-Sam Kim
Journal:  Infect Immun       Date:  2009-06-29       Impact factor: 3.441

7.  Expression of CXC receptor 1 and 2 in esophageal mucosa of patients with reflux esophagitis.

Authors:  Hajime Isomoto; Yusei Kanazawa; Yoshito Nishi; Chun-Yang Wen; Kenichiro Inoue; Shigeru Kohno
Journal:  World J Gastroenterol       Date:  2005-03-28       Impact factor: 5.742

8.  CXCR2 mediates NADPH oxidase-independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation.

Authors:  Veronica Marcos; Zhe Zhou; Ali Onder Yildirim; Alexander Bohla; Andreas Hector; Ljubomir Vitkov; Eva-Maria Wiedenbauer; Wolf Dietrich Krautgartner; Walter Stoiber; Bernd H Belohradsky; Nikolaus Rieber; Michael Kormann; Barbara Koller; Adelbert Roscher; Dirk Roos; Matthias Griese; Oliver Eickelberg; Gerd Döring; Marcus A Mall; Dominik Hartl
Journal:  Nat Med       Date:  2010-09-05       Impact factor: 53.440

Review 9.  CXCR2: a target for pancreatic cancer treatment?

Authors:  Kathleen M Hertzer; Graham W Donald; O Joe Hines
Journal:  Expert Opin Ther Targets       Date:  2013-02-21       Impact factor: 6.902

10.  Type I interferon signaling in hematopoietic cells is required for survival in mouse polymicrobial sepsis by regulating CXCL10.

Authors:  Kindra M Kelly-Scumpia; Philip O Scumpia; Matthew J Delano; Jason S Weinstein; Alex G Cuenca; James L Wynn; Lyle L Moldawer
Journal:  J Exp Med       Date:  2010-01-13       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.